Persistence of Protective Hepatitis B Surface Antibody Titers after Successful Double-Dose Hepatitis B Virus Rescue Vaccination in HIVInfected Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To assess the durability of protective hepatitis B surface antibody (anti-HBs) titers in HIVinfected patients who responded to double-dose hepatitis B virus (HBV) rescue vaccination. Methods: A retrospective chart review was performed for HIV-infected patients who received the double-dose HBV rescue vaccination at 0-, 1-,and 2-month intervals after they had failed conventional HBV vaccination series. A protective antibody response was defi ned as an anti-HBs titer ≥10 mIU/mL. Results: Of 54 HIVinfected patients who received a double-dose HBV rescue vaccination, 44 patients (81.5%) had a positive response and achieved protective anti-HB titers. Of the 44 patients who developed protective anti-HB titers, 33 patients received an evaluation of their anti-HB titers 12 months later. Of the 33 patients, 19 (57.6%) had persistent protective anti-HB titers (persistent responders, PR), and 14 patients (42.4%)lost their protective anti-HB titers (nonpersistent responders,NPR). There were significantly more patients who had an undetectable HIV viral load (<50 copies/mL) at baseline and follow-up in the PR group (11/19, 57.9%) than in the NPR group (3/14, 21.4%, p=0.036). Logistic regression analysis showed that an undetectable HIV viral load at baseline and follow-up (odds ratio, 12.973; 95% confi dence interval, 1.189 to 141.515; p=0.036) was associated with PR. Conclusions: Protective anti-HB titers may decrease over time after successful double-dose HBV rescue vaccination in HIV-infected patients. HIV viral load suppression could improve the persistence of anti-HB titers.
Abstract
Background/Aims: To assess the durability of protective hepatitis B surface antibody (anti-HBs) titers in HIVinfected patients who responded to double-dose hepatitis B virus (HBV) rescue vaccination. Methods: A retrospective chart review was performed for HIV-infected patients who received the double-dose HBV rescue vaccination at 0-, 1-,and 2-month intervals after they had failed conventional HBV vaccination series. A protective antibody response was defi ned as an anti-HBs titer ≥10 mIU/mL. Results: Of 54 HIVinfected patients who received a double-dose HBV rescue vaccination, 44 patients (81.5%) had a positive response and achieved protective anti-HB titers. Of the 44 patients who developed protective anti-HB titers, 33 patients received an evaluation of their anti-HB titers 12 months later. Of the 33 patients, 19 (57.6%) had persistent protective anti-HB titers (persistent responders, PR), and 14 patients (42.4%)lost their protective anti-HB titers (nonpersistent responders,NPR). There were significantly more patients who had an undetectable HIV viral load (<50 copies/mL) at baseline and follow-up in the PR group (11/19, 57.9%) than in the NPR group (3/14, 21.4%, p=0.036). Logistic regression analysis showed that an undetectable HIV viral load at baseline and follow-up (odds ratio, 12.973; 95% confi dence interval, 1.189 to 141.515; p=0.036) was associated with PR. Conclusions: Protective anti-HB titers may decrease over time after successful double-dose HBV rescue vaccination in HIV-infected patients. HIV viral load suppression could improve the persistence of anti-HB titers.
참고문헌 (28)
- Alter MJ, "Epidemiology of viral hepatitis and HIV co-infection", J Hepatol, 44(1 Suppl), pp.S6~S9 (2006)
- Kim JH, "Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States", World J Gastroenterol, 14, pp.6689~6693 (2008)
- Colin JF, "Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men", Hepatology, 29, pp.1306~1310 (1999)
- Thio CL, "HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)", Lancet, 360, pp.1921~1926 (2002)
- Laurence J, "Hepatitis A and B virus immunization in HIV-infected persons", AIDS Read, 16, pp.15~17 (2006)
- Overton ET, "Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons", Clin Infect Dis, 41, pp.1045~1048 (2005)
- Moir S, "Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease", J Allergy Clin Immunol, 122, pp.12~19 (2008)
- van der Vliet HJ, "Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection", J Immunol, 168, pp.1490~1495 (2002)
- Quaglio G, "Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response", Addiction, 97, pp.985~992 (2002)
- Fisman DN, "The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis", Clin Infect Dis, 35, pp.1368~1375 (2002)
- Fonseca MO, "Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose", Vaccine, 23, pp.2902~2908 (2005)
- de Vries-Sluijs TE, "A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients", J Infect Dis, 197, pp.292~294 (2008)
- Cornejo-Juárez P, "Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses", AIDS Res Ther, 3, pp.9~ (2006)
- Cruciani M, "Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients", Vaccine, 27, pp.17~22 (2009)
- Cooper CL, "CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years", Clin Infect Dis, 46, pp.1310~1314 (2008)
- Psevdos G, "Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients", AIDS Patient Care STDS, 24, pp.403~407 (2010)
- Horvath J, "Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses", Clin Infect Dis, 18, pp.339~347 (1994)
- Mannucci PM, "Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs", Arch Intern Med, 149, pp.1333~1337 (1989)
- Marsano LS, "Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults", Am J Gastroenterol, 91, pp.111~115 (1996)
- Kim HN, "Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons", Int J STD AIDS, 19, pp.600~604 (2008)
- Mehta N, "Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination", Vaccine, 28, pp.3672~3678 (2010)
- del Pozo Balado Mdel M, "Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine", J Infect Dis, 202, pp.362~369 (2010)
- Rallón NI, "Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and", or hepatitis C virus, 2009, pp.155, 35~43
- Landrum ML, "Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals", AIDS, 24, pp.545~555 (2010)
- Tuaillon E, "Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patients", AIDS, 21, pp.2343~2345 (2007)
- Ungulkraiwit P, "Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients", Southeast Asian J Trop Med Public Health, 38, pp.680~685 (2007)
- Landrum ML, "Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count", Vaccine, 27, pp.4731~4738 (2009)
- Loke RH, "Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis", J Med Virol, 31, pp.109~111 (1990)